A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer
Sponsor: Tesaro, Inc.
Terminated
The study stopped after meeting pre-specified futility criteria
Other terminated trials from Tesaro, Inc.
- Breast Cancer · Phase PHASE2 · Jul 2022
- Ovarian Cancer · Phase PHASE1 · Sep 2011
- Cancer: Solid Tumors · Phase PHASE1 · Jul 2011
More terminations from Tesaro, Inc.
Other Ovarian Neoplasms trials with similar outcome
A PHASE2 clinical study on Ovarian Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Tesaro, Inc. and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Terminated PHASE2
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tesaro, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Boston, United States , Madrid, Spain , Miami, United States , Montreal, Canada , Málaga, Spain , New York, United States , Ottawa, Canada , Pamplona, Spain , Rochester, United States and 6 more locations